Diplomat Pharmacy Stock Price and Value Analysis

Should you buy Diplomat Pharmacy stock? (NYSE:DPLO). Let's see how it does in our automated value investing analysis system.

DPLO Free Cash Flow Trend

Free Cash Flow trendline for DPLO
Free Cash Flow trendline for Diplomat Pharmacy

Hmm, we can't give any reliable projection for Diplomat Pharmacy's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has amazingly consistent growth!
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company pays no dividend.

Inside the DPLO Numbers

DPLO Price
(Diplomat Pharmacy stock price per share)
[?] PE Ratio versus Sector 783% higher than other Healthcare stocks
[?] PE Ratio versus Industry 84% higher than other Drug Manufacturers - Specialty & Generic stocks
[?] Free Cash Flow Jitter 6%

Is Diplomat Pharmacy Stock on Sale?

Based on our analysis, we believe that you should not buy Diplomat Pharmacy right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy DPLO Stock?

Does Diplomat Pharmacy have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.